Unveiling the Potential of a Novel Liposomal Therapeutic Vaccine Targeting Tau in Alzheimer’s Disease
Time: 4:00 pm
day: Conference Day Two PM
Details:
- Showcasing the phase 2b study testing anti-tau active immunotherapy in preclinical AD
- Utilizing plasma pT217 for prescreening directly from the community (leading to unprecedented diversity in recruitment)
- Implementing a novel imaging analysis methodology looking at tau spread on Tau PET
